Tim Boreham

Food & Agriculture

Health Kick Podcast: The strategy and upside behind global cannabis investment company MMJ

March 8, 2020January 5, 2022 | Tim Boreham

Health & Biotech

Health Kick Podcast: Could oral sprays replace pills as a better means of drug delivery?

March 4, 2020March 4, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Investors hawk-eyed as Immutep closes in on breast cancer drug results

March 1, 2020October 1, 2020 | Tim Boreham

Food & Agriculture

Health Kick Podcast: The ASX’s only medicinal honey player and the advantage of Amazon-aided US exposure

February 26, 2020February 26, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Cochlear can weather the coronavirus-induced China slump

February 23, 2020February 23, 2020 | Tim Boreham

Health & Biotech

Health Kick Podcast: Skyrocketing prescription prices and Trump’s plan for the drug market

February 19, 2020February 19, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers

February 16, 2020December 18, 2023 | Tim Boreham

Health & Biotech

Health Kick Podcast: Coronavirus, HIV and hepatitis are in the sights of Aussie biotech Biotron

February 12, 2020February 12, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: ResMed turbo-charges its sleep apnoea devices, races into new markets

February 9, 2020February 9, 2020 | Tim Boreham

Health & Biotech

Health Kick Podcast: Novel gene targeting therapies, protein disruptors and why ANP’s recent trial success have investors buzzing

February 5, 2020January 15, 2024 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: This is the only ASX-listed biotech in the photodynamic therapy game

February 2, 2020February 2, 2020 | Tim Boreham

Health & Biotech

Health Kick Podcast: Learning from the Swine flu pandemic, the market potential of exosome therapeutics and jumping ASX life-sciences hurdles

January 30, 2020January 30, 2020 | Tim Boreham